Pharma exports rose 10.45% in May to $2.30 billion, says Pharmexcil

N. RAVI KUMAR N. RAVI KUMAR | 06-18 00:20

India’s pharmaceutical exports in May registered a 10.45% increase to $2,301.88 million compared with the $2,084.06 million in the same period previous fiscal.

“It is moving in a positive way and we are optimistic of sustaining growth of not less than 10%,” Pharmaceuticals Export Promotion Council of India Director General Ravi Uday Bhaskar said on the quick estimates numbers released last week by the Centre.

For the first two months of current fiscal, the exports were 8.85% higher at $4,730.66 million ($4,346.03 million). In April, the exports increased 7.36% y-o-y to $2.43 billion ($2.26 billion)

A key component of India’s export basket, pharma exports rose 9.6% year on year to $27.8 billion in 2023-24. Pharmexcil, a body under the Commerce Ministry, is pursuing a target of $31 billion this fiscal.

On the fallout of geo-political crises as well as the resultant logistical challenges, he said there are no disturbances in the focus U.S., Europe and Africa markets that could have a bearing. The Russia-Ukraine war did make a little dent in the exports, but the impact of Russia’s emphasis on localisation is bound to impact more.

Exports to Russia have been negatively growing for last two years. Localisation or Russia’s focus on boosting domestic manufacturing is an issue, he said. “Wars have not made significant impact,” he said, adding exports to the UAE is on the rise as it is emerging as a gateway to different countries.

Pegging the target for FY25 at a record $31 billion, the head of the pharma exporters body under the Commerce Ministry recently cited a shortage of drugs in the key U.S. market amid closure of some units, rising demand in the U.K. and a pickup in the offtake for the African market were factors bound to drive pharma exports.

Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.


ALSO READ

China's Zeekr launches EV in Australia, eyes New Zealand next

Chinese EV maker Zeekr's has begun sales of its first model for Australia. Chinese EV maker Zeekr's ...

Hyundai is for the long haul and do not expect to make quick buck on listing: Dipan Mehta

Dipan Mehta, Director, Elixir Equities.Dipan Mehta, Director, Elixir Equities, says Hyundai compares...

EV chipmaker Wolfspeed set to receive USD 750 million US chips grant

Wolfspeed's devices are used for renewable energy systems, industrial uses and artificial intelligen...

Rio Tinto Q3 iron ore shipments rise, Simandou on track for 2025

Rio said iron ore production from its Iron Ore Company of Canada (IOC) operations fell 11% following...

Hyundai issue is for long-term investors; expect 16-18% growth in next 2-3 yrs: Narendra Solanki

Narendra Solanki, Head Fundamental Research-Investment Services, Anand Rathi Shares & Stock Brok...

Electric car sales have slumped, misinformation is one of the reasons

The politicisation of green initiatives adds to the challenge. When electric vehicles become associa...